Changing lives forever
At Celosia Therapeutics, we are modifying the neuronal microenvironment to defeat neurodegenerative disease.
About
We Develop Solutions For Neurodegenerative Diseases With No Therapeutic Options.
Developing effective treatments for neurodegenerative diseases is challenging and despite recent advances, many people living with neurodegenerative diseases continue to have limited therapeutic options and an overall poor prognosis. Celosia Therapeutics approach arises from advances in gene therapies, and greater understanding of the molecular pathways contributing to neurodegenerative diseases.
Neurodegenerative diseases we are working on:
- ALS/MND/LGD
- Alzheimer’s disease
- Fronto-temporal dementia
- Dravet Syndrome
Our Team
We are scientists, clinicians, innovators, and entrepreneurs redefining the treatment landscape for individuals with devastating neurodegenerative diseases.
Celosia in the News
Contact Us for Media Inquiries at media@celosiatx.com
Video – Interview with Mr Iomar Barrett
Mr Iomar Barrett, Celosia Therapeutics’ Series A investor and hedge fund manager, speaks about…
Video – Interview with Prof Lars Ittner and Prof Yazi Ke
In this video, Celosia Therapeutics co-founders Professor Lars Ittner and Professor Yazi Ke speak ab…
Video – Interview with Celosia Therapeutics CEO Dr Kathryn Sunn
Celosia Therapeutics CEO and Director of Commercialisation at Macquarie University, Dr Kathryn Sunn …
Celosia Secures Landmark $16.75M Funding for Breakthrough ALS Gene Therapy
Sydney, Australia, 28 November 2024 – Celosia Therapeutics, an Australian biotech company developing…
New Research Publication
Published online (16th Feb 2024) in the prestigious journal Neuron is the outcome of over 15 years o…
Celosia Therapeutics Launch
Macquarie University announces the launch of a new company, Celosia Therapeutics, dedicated to deliv…